Chandra P. Belani, MD, deputy director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, discusses results seen with anti—PD-1/PD-L1 treatments in lung cancer.

Belani says at this juncture, there is no  one “winner" amongst these treatments.

Identifying a group of patients that best benefit from anti—PD-1 treatments will be the key to better understanding these agents, says  Belani.

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


PER® New York Lung Cancer Symposium

Chandra P. Belani, MD, deputy director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, discusses results seen with antiâ€“PD-1/PD-L1Â treatments in lung cancer.

Dr. Chandra Belani on Selecting Anti-PD-L1 Agents in Lung Cancer